IL15 and neoplasm: Interleukin‐2 was the first biological immune agent of the interleukin family cytokines used in tumor therapy.[111] In recent years, other interleukins have also shown promise in cancer therapy, including IL‐15, which plays an important role as a biological response regulator of the immune system.[112] However, the clinical application of IL‐15 is limited by its short half‐life and instability in the blood and its lack of cancer targeting ability.